Search results for "Complement C3"

showing 9 items of 69 documents

Suppressive effects of C3b on monocyte-dependent T cell proliferation.

1987

The effect of C3b treatment of human monocytes on secondary antigen-dependent T cell response was studied. When antigen-specific T cell blasts were cultivated together with C3b-treated monocytes the proliferative response was inhibited in a dose-dependent fashion. This suppressive effect was specific for C3b because heat-inactivated C3b or buffer alone had no influence on T cell proliferation. In part, this suppressive effect is mediated through a C3b-induced decreased expression of class II antigens on the surface of treated monocytes, but another suppressive mechanism exists because the C3b pretreatment of monocytes also led to an inhibition of the proliferative response in a class II ant…

T cellT-LymphocytesImmunologyIndomethacinchemical and pharmacologic phenomenaBiologyIn Vitro TechniquesInhibitory postsynaptic potentialT cell responseLymphocyte ActivationMonocytesmedicineImmune ToleranceImmunology and AllergyHumansCells CulturedMonocyteComplement C3Molecular biologyProliferative responsemedicine.anatomical_structureComplement C3dComplement C3bImmunologic MemoryClass II Antigenscirculatory and respiratory physiologyEuropean journal of immunology
researchProduct

Activation of complement by the alternative pathway as a factor in the pathogenesis of periodontal disease.

1976

Dental plaque and a bacterium, Actinomyces viscosus, isolated from plaque that can reproduce periodontal disease in germ-free rats, are activators of complement by the alternative pathway. It is suggested that this process is involved in the pathogenesis of chronic inflammatory periodontal disease.

T-LymphocytesGuinea PigsDental PlaqueAntigen-Antibody ComplexDental plaquePathogenesisstomatognathic systemPeriodontal diseasemedicineActinomycesAnimalsHumansActinomyces viscosusBone ResorptionPeriodontitisGlycoproteinsB-LymphocytesEnzyme Precursorsbusiness.industryMacrophagesGlobulinsGeneral MedicineComplement C3Complement System Proteinsmedicine.diseaseCathepsinsComplement (complexity)RatsEndotoxinsstomatognathic diseasesMicrobial CollagenaseImmunologyAlternative complement pathwaybusinessLancet (London, England)
researchProduct

On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.

1995

Combined treatment with trypsin, cholesterol esterase, and neuraminidase transforms LDL, but not HDL or VLDL, to particles with properties akin to those of lipid extracted from atherosclerotic lesions. Single or double enzyme modifications, or treatment with phospholipase C, or simple vortexing are ineffective. Triple enzyme treatment disrupts the ordered and uniform structure of LDL particles, and gives rise to the formation of inhomogeneous lipid droplets 10-200 nm in diameter with a pronounced net negative charge, but lacking significant amounts of oxidized lipid. Enzymatically modified LDL (E-LDL), but not oxidatively modified LDL (ox-LDL), is endowed with potent complement-activating c…

Very low-density lipoproteinArteriosclerosisImmunologyNeuraminidaseComplement Membrane Attack Complexchemistry.chemical_compoundLipid dropletmedicineExtracellularImmunology and AllergyHumansTrypsinReceptors ImmunologicComplement ActivationGlycoproteinsReceptors Lipoproteinchemistry.chemical_classificationReceptors ScavengerPhospholipase CCholesterolMacrophagesMembrane ProteinsComplement C3Complement System ProteinsArticlesScavenger Receptors Class BSterol EsteraseTrypsinLipid MetabolismLipoproteins LDLEnzymechemistryBiochemistryLow-density lipoproteinlipids (amino acids peptides and proteins)medicine.drugFoam CellsThe Journal of experimental medicine
researchProduct

The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis

2021

Copyright © 2021 Agostinis, Zorzet, Balduit, Zito, Mangogna, Macor, Romano, Toffoli, Belmonte, Morello, Martorana, Borelli, Ricci, Kishore and Bulla. The complement system is a major component of humoral innate immunity, acting as a first line of defense against microbes via opsonization and lysis of pathogens. However, novel roles of the complement system in inflammatory and immunological processes, including in cancer, are emerging. Endometriosis (EM), a benign disease characterized by ectopic endometrial implants, shows certain unique features of cancer, such as the capacity to invade surrounding tissues, and in severe cases, metastatic properties. A defective immune surveillance against…

endometriosisTHP-1 CellsTNF-amast cellsPeritoneal DiseasesCell DegranulationEndometriumImmunology and AllergyOriginal ResearchMice Knockoutmedicine.diagnostic_testendometriosiComplement C3Hep G2 CellsAntibody opsonizationmedicine.anatomical_structureComplement C3aTumor necrosis factor alphaFemaleInflammation MediatorsSignal TransductionImmunologyBiologySettore MED/08 - Anatomia PatologicaImmunofluorescencePeritoneal cavityPeritoneummedicineAnimalsHumansSettore MED/05 - Patologia ClinicaC3complement system...Innate immune systemTumor Necrosis Factor-alphaPeritoneal fluidC3; endometriosis; mast cells; complement system; TNF-aRC581-607Coculture TechniquesImmunity InnateComplement systemImmunity HumoralMice Inbred C57BLDisease Models AnimalCase-Control StudiesTNF-αCancer researchPeritoneal DiseaseImmunologic diseases. Allergymast cell
researchProduct

Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies

2018

The complement and coagulation cascades interact at multiple levels in thrombosis and inflammatory diseases. In venous thrombosis, complement factor 3 (C3) is crucial for platelet and tissue factor (TF) procoagulant activation dependent on protein disulfide isomerase (PDI). Furthermore, C5 selectively contributes to the exposure of leukocyte procoagulant phosphatidylserine (PS), which is a prerequisite for rapid activation of monocyte TF and fibrin formation in thrombosis. Here, we show that monoclonal cofactor-independent antiphospholipid antibodies (aPLs) rapidly activate TF on myelomonocytic cells. TF activation is blocked by PDI inhibitor and an anti-TF antibody interfering with PDI bin…

inorganic chemicals0301 basic medicineComplement factor I030204 cardiovascular system & hematologyMonocytesImmunoglobulin GThromboplastinThrombosis and HemostasisMice03 medical and health sciencesTissue factor0302 clinical medicineimmune system diseasesmedicineAnimalsPlateletneoplasmsBlood CoagulationMice KnockoutVenous ThrombosisComplement component 5biologyChemistryMonocyteComplement C5Complement C3Hematologynervous system diseasesbody regions030104 developmental biologymedicine.anatomical_structureCoagulationAntibodies Antiphospholipidbiology.proteinCancer researchAntibodyBlood Advances
researchProduct

Analysis of complement C3 activation products in human atherosclerotic lesions.

1991

Abstract Cleavage of the complement C3 protein is essential for complement activation. Saline extracts of human atherosclerotic lesions were examined by various techniques for the presence of C3 cleavage fragments. Crossed intermediate gel immunoelectrophoresis revealed that native C3 was the predominate C3 protein in extracts and that the C3dg fragment was also detected. SDS-PAGE/ Western blot analyses of lesion extracts employing monoclonal antibodies directed at C3c and C3dg fragment determinants demonstrated molecular weight bands corresponding to the known molecular weights of all the physiologic C3 cleavage fragments, except Cab which is known to have a short half-life. After C3, the …

medicine.diagnostic_testMolecular massArteriosclerosisBlotting WesternEnzyme-Linked Immunosorbent AssayImmunoelectrophoresisArteriesComplement C3BiologyCleavage (embryo)C3-convertasePeptide FragmentsComplement systemBlotBiochemistryWestern blotComplement C3bmedicineHumansLipid particleCardiology and Cardiovascular MedicineComplement ActivationImmunoelectrophoresisAtherosclerosis
researchProduct

Monoclonal antibodies against components of the classical pathway of complement.

1989

Activation of the classical pathway of complement involves several binding and enzymatic cleavage processes. Binding and enzymatic activation results in the appearance of new structures in the individual components. This report describes the different activation steps for C1q, C1r, C1s, C4 and C2 and summarizes monoclonal antibodies reported so far which recognize either conserved epitopes or activation-dependent epitopes with particular emphasis on neoepitopes occurring during the activation cascade.

medicine.drug_classComplement Activating EnzymesImmunologyComplement C3-C5 ConvertasesComplement C3-C5 ConvertasesMonoclonal antibodyEpitopeClassical complement pathwayEpitopesComplement C1medicineComplement Pathway ClassicalComplement C1qComplement ActivationComplement component 2biologyChemistryComplement C1qAntibodies MonoclonalComplement C4HematologyComplement System ProteinsComplement C2Complement systemBiochemistrybiology.proteinAntibodyComplement and inflammation
researchProduct

Is cell salvage safe in liver resection? A pilot study

2007

Abstract Study Objective To investigate the quality of cell salvaged (CS) blood in patients undergoing hemihepatectomy (study group) and compare it with CS-blood from aortic surgery (control group). Design Observational study. Setting Operating room in a university hospital. Measurements 6 patients undergoing hemihepatectomy or aortobifemoral bypass with intraoperative blood loss of more than 800 mL. Samples were drawn from the central venous catheter, from the reservoir of a CS recovery system, and from the processed blood in each patient to determine interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor (TNF), complement C3a, and the terminal complement complex C5b-9. Microbiological ana…

medicine.medical_specialtyBlood transfusionmedicine.medical_treatmentCellPilot ProjectsComplement Membrane Attack ComplexResectionBlood Transfusion AutologousmedicineHepatectomyHumansInterleukin-6business.industryInterleukin-8InterleukinBacterial InfectionsInterleukin-10Complement systemSurgeryAnesthesiology and Pain Medicinemedicine.anatomical_structureCytokineComplement C3aErythrocyte TransfusionbusinessAnaerobic exerciseCentral venous catheterJournal of Clinical Anesthesia
researchProduct

Studies on the mechanism of PMN activation II. by triggering the alternative pathway of complement activation

1982

By means of cobra venom factor (CVF) it is demonstrated that the stimulation of hexosemonophosphate shunt (HMPS) of human polymorphonuclear leukocytes (PMN) by zymosan (Z) and dextran sulfate (DS) is caused by at least two modes of activation: (a) via activation caused by phagocytosis, (b) via activated alternative pathway of complement activation (APC). Active factors of APC presented with phagocytizable objects strongly enhance activation of PMN. The effect of APC can be observed in serum-containing as well as in serum-free cultures. It can be demonstrated that in serum-free cultures the factors of APC participating in the activation of PMN are supplied by monocytes. By the use of synthet…

medicine.medical_specialtyNeutrophilsPhagocytosisComplement Pathway AlternativeDose-Response Relationship ImmunologicStimulationMonocyteschemistry.chemical_compoundPhagocytosisInternal medicinemedicineHumansComplement ActivationHematologyChemistryDextran SulfateZymosanZymosanDextransComplement C3HematologyGeneral MedicinePeptide FragmentsCell biologyComplement systemDextran sulfateBiochemistryComplement C3aAlternative complement pathwayCobra venom factorBlut
researchProduct